Technical Analysis for ADMS - Adamas Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 18.67 -5.99% -1.19
ADMS closed down 5.99 percent on Tuesday, September 18, 2018, on 1.77 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ADMS trend table...

Date Alert Name Type % Chg
Sep 18 Lower Bollinger Band Walk Weakness 0.00%
Sep 18 Below Lower BB Weakness 0.00%
Sep 18 Down 3 Days in a Row Weakness 0.00%
Sep 18 Down 4 Days in a Row Weakness 0.00%
Sep 18 Oversold Stochastic Weakness 0.00%
Sep 17 MACD Bearish Signal Line Cross Bearish -5.99%
Sep 17 Expansion Breakdown Bearish Swing Setup -5.99%
Sep 17 Stochastic Reached Oversold Weakness -5.99%
Sep 17 Multiple of Ten Bearish Other -5.99%
Sep 17 BB Squeeze Ended Range Expansion -5.99%

Older signals for ADMS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Adamas Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for chronic disorders of the central nervous systems (CNS) in the United States. The company is developing its lead product candidate, ADS-5102 that has completed a Phase 2/3 clinical study for levodopa induced dyskinesia, a complication of Parkinson's disease; and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. It is also developing ADS-8800 and ADS-9000 series of products for use in a range of CNS indications; ADS-8704, a fixed-dose combination of memantine and donepezil for the treatment of moderate to severe dementia related to alzheimer's disease; and ADS-8902, a triple combination antiviral drug therapy for influenza. In addition, the company develops memantine-based therapeutics portfolio includes Namenda XR and MDX-8704, which are used in the treatment of dementia associated with moderate to severe alzheimer's disease. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Is ADMS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 44.0
52 Week Low 17.68
Average Volume 521,418
200-Day Moving Average 28.5061
50-Day Moving Average 23.9272
20-Day Moving Average 22.1605
10-Day Moving Average 21.875
Average True Range 1.1234
ADX 17.7
+DI 9.6763
-DI 31.2454
Chandelier Exit (Long, 3 ATRs ) 19.9898
Chandelier Exit (Short, 3 ATRs ) 22.0202
Upper Bollinger Band 24.2695
Lower Bollinger Band 20.0515
Percent B (%b) -0.33
BandWidth 19.033867
MACD Line -0.858
MACD Signal Line -0.6026
MACD Histogram -0.2554
Fundamentals Value
Market Cap 420.34 Million
Num Shares 22.5 Million
EPS -2.99
Price-to-Earnings (P/E) Ratio -6.24
Price-to-Sales 2373.51
Price-to-Book 4.03
PEG Ratio -0.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.68
Resistance 3 (R3) 20.90 20.44 20.35
Resistance 2 (R2) 20.44 19.93 20.34 20.23
Resistance 1 (R1) 19.56 19.62 19.33 19.34 20.12
Pivot Point 19.10 19.10 18.99 19.00 19.10
Support 1 (S1) 18.22 18.59 17.99 18.00 17.22
Support 2 (S2) 17.76 18.28 17.66 17.11
Support 3 (S3) 16.88 17.76 17.00
Support 4 (S4) 16.66